



GENOMICS | DIAGNOSTIC TESTS | GENETICS | R&D

## GENOMIC VISION: REPORT OF THE LSR R&D DAY ON OCTOBER 16, 2017

- A large panel of key opinion leaders presented the competitiveness of molecular combing in the fields of DNA replication and gene editing
- The Company reiterated the presentation of research conducted with, and published by, Editas Medicine on the use of molecular combing to assess DNA integrity after CRISPR/Cas9 editing

**Bagneux (France), October 18, 2017 – 8 pm (CEST) - Genomic Vision (Euronext: FR0011799907 – GV)**, a company specialized in the development of diagnostic tests for the early detection of cancers and genetic diseases, today reports of its second R&D Day which took place on October 16 in Paris and was attended by clients, investors, analysts and journalists. This second edition was aimed at presenting a global overview of the life science research (LSR) activities of the Company.

In his introduction speech, Aaron Bensimon, Co-founder and CEO of Genomic Vision, highlighted the interest for molecular combing in the markets of DNA replication and gene editing. *“Our entry on the LSR market, which began in mid-2016 through targeting both DNA replication and gene editing, was an addition to our historical activity in the IVD. Today, we are very proud of the results already obtained for example with the technological collaboration with AstraZeneca in the research for new oncology treatments. More widely, our technology seems particularly successful and appreciated by the scientific community to study DNA damages and repairs in the field of cancer. This is both true in the field of DNA replication as well as in gene editing.”*

Prof. Antonella Russo of the University of Padova (Italy) and Prof. Alex Bishop of the University of Texas Health Science Center at San Antonio presented their use of molecular combing in the field of DNA replication and the importance of its analysis: *“Combing constitutes a very promising tool for the development of new personalized therapies as this technology offers useful data from the study of a single DNA molecule. This characteristic allows us to better identify and understand the origin of DNA replication, its multiplication and its speed of replication”*, summarized Prof. Russo and Prof. Bishop.

Subsequently, Lucia Cinque, Head of Product Innovation at Genomic Vision and Naranayan Gopalan, VP Disruptive Biologics at Voisin Consulting Life Sciences, have presented the key role played by combing in gene editing. Lucia Cinque presented the research conducted jointly with Editas Medicine. *“Our research, initiated a year ago, has been presented last July during the 3rd CSHL Conference in New York. The analysis using combing technology, which enables high sensitivity and no bias, showed to be key in the profiling of genetic modifications induced by the CRISPR/Cas9 system. By associating molecular combing with the reference technologies in this field, such as the NGS, it has been possible to detect rare events and reach levels of characterization close to 100%”*, declared Lucia Cinque.

Naranayan Gopalan explained the specific and strict regulatory context which will be compulsory for gene editing tools in human therapy: *“The necessity of a quality control tool is indisputable to respond to the regulatory challenges. This tool should allow to assess all the effects in a precise, reliable, complete and reproducible manner. The simple clinical examination of the treatment’s benefits will probably not be sufficient for the Health*

*Authorities; they should probably enforce a follow-up in the long term of the possible effects on DNA.”*

This second edition of the R&D day ended with a round table including all speakers as well as Mr. Anderson Wang, Senior scientist at AstraZeneca (Cambridge, UK).

The conference video will be available on the Genomic Vision website soon.

## ABOUT GENOMIC VISION

GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing to identify genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of the pharmaceutical companies, the leaders of the diagnostic industry and the research labs. The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 60 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext's regulated market in Paris (Euronext: GV - ISIN: FR0011799907). For further information, please visit [www.genomicvision.com](http://www.genomicvision.com)

## CONTACTS

### Genomic Vision

Aaron Bensimon  
Co-founder, Chairman & CEO  
Tel.: +33 1 49 08 07 50  
[investisseurs@genomicvision.com](mailto:investisseurs@genomicvision.com)

### Ulysse Communication

Press Relations  
Bruno Arabian  
Tel.: +33 1 81 70 96 30  
[barabian@ulyse-communication.com](mailto:barabian@ulyse-communication.com)

### NewCap

Investor Relations  
Dušan Orešanský / Emmanuel Huynh  
Tel.: +33 1 44 71 94 92  
[gv@newcap.eu](mailto:gv@newcap.eu)



Member of **CAC® Mid & Small** and **CAC® All-Tradable** indexes

## FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision ([www.genomicvision.com](http://www.genomicvision.com)) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.